Research & Development World

  • Home Page
  • Topics
    • Aerospace
    • Archeology
    • Automotive
    • Biotech
    • Chemistry
    • COVID-19
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Market Pulse
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
      • Software
    • Semiconductors
  • 2021 R&D 100 Award Winners
    • R&D 100 Awards
    • 2020 Winners
    • Winner Archive
  • Resources
    • Digital Issues
    • Podcasts
    • Subscribe
  • Global Funding Forecast
  • Webinars

Merrion Collaborating With Novo Nordisk

By R&D Editors | December 22, 2010

Merrion Pharmaceuticals Plc, a publicly listed product development company, announced the signing of a Collaboration and Option agreement with Novo Nordisk. The agreement will evaluate the ability of Merrion’s patented GIPET technology to boost the oral bioavailability of an undisclosed proprietary compound.

Following the feasibility studies, Novo Nordisk will have the option to enter into a further licensing agreement for Merrion’s GIPET technology. The financial terms of a possible future licensing agreement have been pre-agreed.

As part of the agreement Merrion has granted Novo Nordisk a warrant to acquire ordinary shares of up to EURO1,500,000 in Merrion at yesterday’s closing share price. The warrant will be exercisable for 20 business days commencing on the day following the signing of a license agreement.

Merrion can request Novo Nordisk to acquire up to €1,500,000 worth of shares in Merrion at yesterday’s closing share price (EURO3.00) exercisable for 20 business days commencing on the day following the signing of a license agreement.

Commenting on the announcement, John Lynch, CEO, Merrion Pharmaceuticals, said, “We are very pleased to be entering into another agreement with Novo Nordisk with our unique GIPET technology. This agreement further strengthens the links between the two companies following the license agreements for oral GLP-1 and Insulin respectively. This, along with the other recently announced agreements with Rebel and a top 10 pharma company, means that Merrion has an additional 6 compounds in its preclinical pipeline.”

Date: December 22, 2010
Source: Merrion Pharmaceuticals Plc 

Related Articles Read More >

Certara’s COVID vaccine model is focus of Episode 8 of R&D 100 – The Podcast
New dangers in the woods — and the hope that research offers us
PerkinElmer participating at Bio-IT World Conference & Expo
Nalu Medical’s mIPG is focus of Episode 7 of R&D 100 – The Podcast
2021 R&D Global Funding Forecast

Need R&D World news in a minute?

We Deliver!
R&D World Enewsletters get you caught up on all the mission critical news you need in research and development. Sign up today.
Enews Signup

R&D World Digital Issues

February 2020 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R& magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • 2022 Global Funding Forecast

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • Home Page
  • Topics
    • Aerospace
    • Archeology
    • Automotive
    • Biotech
    • Chemistry
    • COVID-19
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Market Pulse
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
      • Software
    • Semiconductors
  • 2021 R&D 100 Award Winners
    • R&D 100 Awards
    • 2020 Winners
    • Winner Archive
  • Resources
    • Digital Issues
    • Podcasts
    • Subscribe
  • Global Funding Forecast
  • Webinars